Medical News

RSS

3Pea International files registration statement on Form 10

3Pea International Inc., a payment solutions company, today announced that it has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) to register its common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934.

20 Sep 2010

Actress Claire Danes joins thumbprint mosaic in Save the Children's EVERY ONE campaign

Emmy award winning actress Claire Danes will join millions of people who've added their thumbprints to an innovative and unique global petition at Grand Central Terminal, lead by global humanitarian organisation Save the Children.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

Medical Accounts Systems, Jorge M. Abril, P.A. launch Healthcare Provider Payment

The staff at Medical Accounts Systems and the attorneys at Jorge M. Abril, P.A. are pleased to announce the launch of Healthcare Provider Payment, a blog dedicated to helping healthcare professionals and other interested parties stay abreast of relevant news and emerging trends in healthcare reimbursement, from insurance litigation news and Managed Care contracting issues, to health law and policy in general.

20 Sep 2010

Florida Hospital Fish Memorial acquires Toshiba's Xario XG ultrasound systems

Today's hospitals are under pressure to enhance patient care and streamline workflow while containing costs. To achieve this goal, Florida Hospital Fish Memorial acquired four XarioXG ultrasound systems from Toshiba America Medical Systems, Inc., to create imaging consistency across various departments.

20 Sep 2010

PAREXEL and Eli Lilly enter strategic functional service provider relationship

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the establishment of a strategic functional service provider relationship with Eli Lilly and Company, a global pharmaceutical company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region. PAREXEL will assist Lilly in bringing greater efficiencies to its clinical research studies to help meet Lilly's development and commercialization goals.

From Parexel 20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010

Stereotaxis receives 100th patent for interventional medicine

Stereotaxis, Inc. today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.

20 Sep 2010

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.

20 Sep 2010

High-intensity exercise video game to improve health of middle aged men

Sedentary middle-aged men on Teesside in the North East of England could soon be using a high-intensity exercise video game to improve their health. For researchers at Teesside University have developed an alternative to the Nintendo Wii which doesn't allow users to cheat. Now they plan to put it to the test by getting middle-aged members of workingmen's clubs to take part in 'virtual' boxing matches with a computer-generated opponent.

20 Sep 2010

Prestige Brands agrees to acquire Blacksmith Brands stock for $190 million

Prestige Brands Holdings, Inc., a leading marketer of branded consumer products, today announced that it has entered into a definitive agreement to acquire 100% of the stock of Blacksmith Brands Holdings, Inc., for $190 million in cash.

20 Sep 2010

Safran to acquire L-1 Identity Solutions' businesses

Safran announced today that it has entered into a definitive agreement with L-1 Identity Solutions, a leading identity management provider in the United States, for Safran to acquire the operating and holding company of L-1 and its biometric and enterprise access solutions, secure credentialing solutions and enrollment services businesses, for a total cash amount of USD 1.09 billion.

20 Sep 2010

Cord Blood America acquires controlling interest of Biocordcell Argentina

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has purchased controlling interest, 50.1 percent, of Biocordcell Argentina S.A. (BioCells, Inc.).

20 Sep 2010

Environmental factors are cause of subarachnoid haemorrhage in most cases

The Nordic twin study investigating the heritability of subarachnoid haemorrhage (SAH) suggests that the role of genetic factors underlying the development of SAH is less than previously believed.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

Aeris Therapeutics receives CE Mark approval for AeriSeal System to treat emphysema

Aeris Therapeutics, a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, today announced that it has received CE Mark approval for its AeriSeal System.

20 Sep 2010

FluimediX receives fund for NanoCycler development

FluimediX, a point-of-care diagnostic company, announced today that it has received funding for the continued development of the NanoCycler, a diagnostic platform for the measurement of relevant genetic mutations in patients. The proceeds of this financing round will be dedicated to developing a diagnostic test for Warfarin™ metabolism.

20 Sep 2010